[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632144":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":36,"locations":42,"responsibleParty":62,"collaborators":27,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":27,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":27,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":45,"whyStopped":27,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Liposomal Bupivacaine Group","EXPERIMENTAL","Participants assigned to this arm will receive ultrasound-guided adductor canal block (ACB) and infiltration between the popliteal artery and capsule of the knee (IPACK) block using liposomal bupivacaine 6.65%. A total volume of 40 mL will be administered, divided as 20 mL for the ACB and 20 mL for the IPACK block",[13],"Drug: Liposomal bupivacaine (LB)",{"label":15,"type":16,"description":17,"interventionNames":18},"Ropivacaine with perineural adjuncts Group","ACTIVE_COMPARATOR","Participants assigned to this arm will receive ultrasound-guided adductor canal block (ACB) and infiltration between the popliteal artery and capsule of the knee (IPACK) block using ropivacaine 0.375% supplemented with perineural dexmedetomidine 1 μg\u002Fkg or perineural dexamethasone 4 mg. A total volume of 40 mL will be administered, divided as 20 mL for the ACB and 20 mL for the IPACK block.",[19,20],"Drug: Ropivacaine with Perineural Dexamethasone","Drug: Ropivacaine with Perineural Dexmedetomidine",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Liposomal bupivacaine (LB)","Liposomal bupivacaine 6.65% injection. A total volume of 40 mL will be administered as ultrasound-guided adductor canal block (ACB) and infiltration between the popliteal artery and capsule of the knee (IPACK) block, divided as 20 mL for each block, prior to surgical incision.",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Ropivacaine with Perineural Dexamethasone","Ropivacaine 0.375% combined with dexamethasone 4 mg per block (total 8 mg) as a perineural adjunct. A total volume of 40 mL will be administered as ultrasound-guided adductor canal block (ACB) and infiltration between the popliteal artery and capsule of the knee (IPACK) block, divided as 20 mL for each block",[15],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Ropivacaine with Perineural Dexmedetomidine","Ropivacaine 0.375% with dexmedetomidine 1 μg\u002Fkg (actual body weight). Total 40 mL (20 mL per block) via ultrasound-guided ACB and IPACK",[15],[37],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"Xi Wu","CONTACT","+8615871715431","wu2018whuh@163.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei","430022","China","CN",{"type":52,"coordinates":53},"Point",[54,55],114.26667,30.58333,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":27,"email":61},"You-nian Xu, Professor","+8613657263415","xyn0103@hust.edu.cn",{"type":63,"investigatorFullName":38,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100632144","liposomal-bupivacaine-versus-ropivacaine-with-perineural-dexamethasone-or-dexmedetomidine-as-adjuncts-for-adductor-canal-block-combined-with-ipack-block-in-total-knee-arthroplasty-100632144",false,"NCT07509866","Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal Block Combined With IPACK Block in Total Knee Arthroplasty","A Randomized Trial of Liposomal Bupivacaine, Ropivacaine With Perineural Dexamethasone, and Ropivacaine With Perineural Dexmedetomidine for Adductor Canal Block Combined With IPACK Block in Total Knee Arthroplasty","Inclusion Criteria:\n\n* Patients scheduled for elective primary unilateral total knee arthroplasty\n* Age ≥ 18 years and ≤ 80 years\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Body mass index (BMI) ≥ 18 kg\u002Fm² and ≤ 35 kg\u002Fm²\n* Ability to understand and provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or contraindication to local anesthetics (bupivacaine, ropivacaine), dexamethasone, dexmedetomidine, or opioids\n* Infection at the injection site\n* Coagulopathy or current use of anticoagulants\n* Severe cardiovascular disease (New York Heart Association \\[NYHA\\] functional class III or IV, or recent myocardial infarction within 6 months)\n* Severe hepatic impairment (Child-Pugh class C) or renal impairment (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Uncontrolled hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg despite medical therapy)\n* Uncontrolled diabetes mellitus (HbA1c \\> 8.5%)\n* Bilateral TKA or revision TKA\n* Chronic opioid use (daily opioid consumption for \\> 3 months prior to surgery)\n* Participation in another interventional clinical trial within 30 days prior to enrollment\n* Inability to communicate with study personnel or complete pain assessments (e.g., language barrier, cognitive impairment)","ALL","18 Years","80 Years",{"count":76,"type":77},90,"ESTIMATED","INTERVENTIONAL",[80],"NA","Effective postoperative pain management remains a cornerstone of enhanced recovery protocols following total knee arthroplasty (TKA). Inadequate analgesia not only compromises patient satisfaction but also impedes early mobilization and rehabilitation, thereby increasing the risk of perioperative complications. Current multimodal analgesic strategies frequently incorporate regional techniques, with the adductor canal block (ACB) and infiltration between the popliteal artery and capsule of the knee (IPACK) block emerging as established modalities that provide motor-sparing analgesia.\n\nDespite their widespread adoption, the optimal local anesthetic regimen for these blocks remains undefined. While liposomal bupivacaine has garnered interest for its extended duration of action, its clinical efficacy relative to conventional local anesthetics combined with perineural adjuncts remains a subject of ongoing debate. Specifically, perineural dexamethasone and dexmedetomidine have each demonstrated the capacity to prolong the analgesic duration of ropivacaine; however, direct comparative data among these three distinct strategies-liposomal bupivacaine alone versus ropivacaine supplemented with either adjunct-are notably limited.\n\nGiven the absence of head-to-head randomized trials evaluating these three clinically viable techniques, the optimal approach to maximize analgesic duration while minimizing opioid-related adverse effects remains unclear. This study therefore aims to compare the analgesic efficacy and safety profiles of liposomal bupivacaine, ropivacaine with perineural dexamethasone, and ropivacaine with perineural dexmedetomidine when administered via ACB and IPACK blocks in patients undergoing TKA.",[83,84,85,86],"Total Knee Anthroplasty","Nerve Block","Ropivacaine","Liposomal Bupivacaine",[88,89,90,91,92,93,94,95,96],"total knee arthroplasty","adductor canal block","IPACK block","liposomal bupivacaine","ropivacaine","perineural adjuncts","dexamethasone","dexmedetomidine","multimodal analgesia","2026-04-09",{"date":99,"type":100},"2026-04-14","ACTUAL",{"date":97,"type":100},{"date":103,"type":77},"2026-12-30",{"name":5,"class":6},1]